Trial Profile
A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Cidofovir (Primary)
- Indications Polyomavirus infections
- Focus Therapeutic Use
- 05 Feb 2024 Planned End Date changed from 15 Mar 2024 to 15 Mar 2026.
- 05 Feb 2024 Planned primary completion date changed from 15 Mar 2024 to 15 Mar 2026.
- 30 Mar 2023 Planned End Date changed from 1 Mar 2023 to 15 Mar 2024.